Cannasouth is based in the Waikato heartland of New Zealand, where it has established hi-tech laboratories, manufacturing research and cultivation facilities.
Our goal is the development of next-generation cannabinoid medicines that support patients’ health outcomes and improve their quality of life.
Phytocannabinoids are remarkable compounds able to interact with the human and animal internal ECS and by doing so are able to provide improved health and wellbeing outcomes for patients.
We believe in using clean, sustainable, and natural growing environments for our cultivars. Giving patients, doctors and clinicians the confidence of knowing that our cannabinoid medicines originate from a pure natural source.
Research and Science
Cannasouth conducts drug discovery, pharmacological bioavailability and drug delivery research programs that support the development of advanced cannabinoid medicines, targeting a broad range of health conditions that patients suffer from.
The quality of our cannabinoid medicines will be a reflection of our commitment to offer patients the highest standard of cannabinoid therapeutic compounds. Patients and their quality of life are at the centre of our product development strategy.
Cannasouth will be formulating medicinal cannabinoid therapeutic products of the highest standard. Using the best quality ingredients and manufacturing techniques to create medicines unrivalled regarding cannabinoid purity, quality and efficacy.
Cannasouth is currently undergoing certification for ISO 9001, 14001 and 45001 Integrated Management System (IMS) Standards. ISO international standards ensure that products and services are safe, reliable and of good quality.
Providing GMP certified medicines that are safe, traceable and effective is at the heart of Cannasouth. “Good Manufacturing Practice” is the globally recognised quality control system used in pharmaceutical product manufacturing.